ARGX vs RPRX
argenx SE and Royalty Pharma plc, both Healthcare
argenx SE is the larger company at $56B against $31B. On trailing earnings RPRX is the cheaper of the two at a P/E of 30.3 against 42.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year RPRX returned +59% against +12% for ARGX. The RyuScore puts RPRX ahead, 52 against 11 out of 100.
| Figure | ARGX | RPRX |
|---|---|---|
| Last close | $825 | $56.90 |
| Market cap | $56B | $31B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 42.2 | 30.3 |
| 1-year return | +12% | +59% |
| 5-year return | +156% | +61% |
| RyuScoresector-relative, 1–10 | 11/100 | 52/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
argenx SE
Revenue of $2.5B in H2 2025, net income $877M.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.